Oxford Vaccine Group launches world’s first Phase I Bundibugyo ebolavirus vaccine trial - The HinduBusinessLine
• The Oxford Vaccine Group has launched the world's first Phase I clinical trial for a vaccine targeting the Bundibugyo ebolavirus. • The initiative is being supported by India's Serum Institute to develop a viable immunization strategy against this specific strain. • This trial is critical for expanding global preparedness against Ebola outbreaks and developing targeted vaccines for diverse virus variants.
thehindubusinessline.com

